Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a single center. single arm, open-label study to determine the safety of mRNA
modified HBV-TCR redirected T-cells and to analyze the changes in tumor microenvironment
caused by these HBV-TCR redirected T-cells in subjects with HBV-related HCC who are not
amenable to/failed conventional treatment.